Effectiveness of a Typhoid Conjugate Vaccine in DRC

Launched by INTERNATIONAL VACCINE INSTITUTE · Nov 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a vaccine called Typbar-TCV® in preventing typhoid fever, a serious illness caused by bacteria. The trial is taking place in Kisantu, Democratic Republic of the Congo (DRC), and aims to see how well a single dose of this vaccine works when given to children aged 9 months to under 16 years during a mass vaccination campaign. Researchers want to find out if the vaccine can reduce the number of children who develop typhoid fever confirmed by blood tests.

To be eligible for this study, children must live in the Kisantu Health Zone and be between 9 months and 15 years old at the time of vaccination. Parents or guardians need to give their permission for their child to participate, and children aged 12 to under 16 will also need to agree to take part. Some children may not be able to join if they have a known allergy to any vaccine ingredients, have certain health conditions, or if they are pregnant. Those who participate will receive the vaccine, and researchers will monitor them to see how well it works in preventing the disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Parent/guardian willing and able to provide informed consent; assent will be sought for participants between 12 and \<16 years of age
• • Resident of the defined study area, Kisantu Health Zone at the time of vaccination
• • Age between 9 months and \<16 years (i.e., ≤15 years and 364 days) on the day of vaccination
• Exclusion Criteria:
• • The participant has a known allergy to any of the vaccine components,
• • Any medical reason perceived to increase risk to health posed by vaccination as judged by a medical professional
• • Self-reported pregnancy in females greater or equal to 11 years of age who have reported menarche